Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors.
Michael ChenDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0003-0694-6641
Natalia NeverovaDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.
Shili XuCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-4933-8673
Krit SuwannaphoomDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0009-0009-6036-829X
Gentian LluriDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-4000-8993
Mikayla TambolineCrump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-3675-2904
Sandra DuarteDivision of Laboratory and Animal Medicine, University of California, Los Angeles, California, USA.ORCID 0009-0004-7671-2589
Michael C FishbeinDepartment of Pathology and Laboratory Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-6591-6306
Yuan LuoState Key Laboratory of Transducer Technology, Shanghai Institute of Microsystem and Information Technology, Chinese Academy of Sciences, Shanghai, People's Republic of China.ORCID 0000-0003-3153-7495
René R Sevag PackardDivision of Cardiology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, California, USA.ORCID 0000-0002-8520-5843
Funding
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARION Xenofon CHATZIIOANNOU · 1985 to 2026
$134.5M
UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Small animal combined PET/CT systemS10OD026917 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI CHATZIIOANNOU, ARION XENOFON · 2020 to 2020
$750k
Dissecting mechanisms of anthracycline-induced cardiotoxicityR56HL158569 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PACKARD, RENE R.S. · 2022 to 2022
$390k
BLRD VA I01 BX004558HHS | National Institutes of Health (NIH) 1S10OD026917-01A1HHS | National Institutes of Health (NIH) 2P30CA016042-44HHS | National Institutes of Health (NIH) NCATS UCLA CTSI UL1TR001881HHS | National Institutes of Health (NIH) R56HL158569NCATS NIH HHS UL1 TR001881NCI NIH HHS P30 CA016042NHLBI NIH HHS R56 HL158569NIH HHS S10 OD026917UC | University of California, Los Angeles (UCLA)U.S. Department of Veterans Affairs (VA) BX004558
6 · The paper itself
Abstract
Distinguishing quiescent from rupture-prone atherosclerotic lesions has significant translational and clinical implications. Electrochemical impedance spectroscopy (EIS) characterizes biological tissues by assessing impedance and phase delay responses to alternating current at multiple frequencies. We evaluated invasive 6-point stretchable EIS sensors over a spectrum of experimental atherosclerosis and compared results with intravascular ultrasound (IVUS), molecular positron emission tomography (PET) imaging, and histology. Male New Zealand White rabbits (n = 16) were placed on a high-fat diet, with or without endothelial denudation via balloon injury of the infrarenal abdominal aorta. Rabbits underwent in vivo micro-PET imaging of the abdominal aorta with
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.
Invasive electrochemical impedance spectroscopy with phase delay for experimental atherosclerosis phenotyping. · full record | Socratic